标题
How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?
作者
关键词
-
出版物
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 12, Issue 1, Pages 1-11
出版商
Springer Nature
发表日期
2011-01-25
DOI
10.1007/s11864-010-0137-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
- (2014) N Fleeman et al. HEALTH TECHNOLOGY ASSESSMENT
- Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
- (2010) Yumi Asukai et al. BMC CANCER
- Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
- (2010) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer
- (2010) P. A. Bradbury et al. JNCI-Journal of the National Cancer Institute
- Targeted cancer therapies
- (2010) Saurabh Aggarwal NATURE REVIEWS DRUG DISCOVERY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
- (2009) Yu Yang Soon et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: It Does Not Always Fade With Time
- (2009) Jean-Yves Douillard JOURNAL OF CLINICAL ONCOLOGY
- Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
- (2009) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal
- (2009) Panagiota Vrouchou et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib
- (2009) Katherine A. Lyseng-Williamson PHARMACOECONOMICS
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel Strategy for Treatment of Metastatic Pulmonary Tumors: Radiofrequency Ablation in Conjunction with Surgery
- (2008) Yoshifumi Sano et al. Journal of Thoracic Oncology
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search